Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

10055	Companies
205316	Keywords
135542	Articles
108846	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 02/01/2024 at 13:00, 2 years 1 month ago

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year

Financial Results Conference Call Moderna Inc Webcast MRNA Medicine
PRESS RELEASE

published on 01/31/2024 at 23:45, 2 years 1 month ago

Moderna Named to Fortune's List of World's Most Admired Companies
Moderna, Inc. has been recognized on Fortune's World's Most Admired Companies list, positioning among the top-50 companies. The company focuses on mRNA medicine for disease prevention and treatment, recognized for innovation and public health impact

Moderna Inc. Fortune Most Admired Companies MRNA Medicine Corporate Reputation
PRESS RELEASE

published on 01/08/2024 at 13:00, 2 years 2 months ago

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET.

Moderna Inc Financial Updates COVID-19 Market Share Late-stage Programs MRNA Development Programs
PRESS RELEASE

published on 12/20/2023 at 22:05, 2 years 2 months ago

Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PRESS RELEASE

published on 12/15/2023 at 00:00, 2 years 3 months ago

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
PRESS RELEASE

published on 12/14/2023 at 12:30, 2 years 3 months ago

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
PRESS RELEASE

published on 12/12/2023 at 14:00, 2 years 3 months ago

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
PRESS RELEASE

published on 12/07/2023 at 13:00, 2 years 3 months ago

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
PRESS RELEASE

published on 11/14/2023 at 13:00, 2 years 4 months ago

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
PRESS RELEASE

published on 11/08/2023 at 22:15, 2 years 4 months ago

Moderna to Present at Upcoming Conferences in November 2023

Accesswire

Published on 03/19/2026 at 14:20, 41 minutes ago

CBMJ CEO Rips Legacy Liberal Media Over Iran Coverage on The Schaftlein Report
Published on 03/19/2026 at 13:50, 1 hour 11 minutes ago

Predictiv AI Appoints Multi-Agent Systems Pioneer Professor George Rzevski as Strategic Advisor to Advance Swarm AI Platforms
Published on 03/19/2026 at 13:30, 1 hour 31 minutes ago

Hillcrest Energy Technologies CEO Don Currie Discusses ZVS Technology and Commercialization Progress in Stocks To Watch Investor Interview
Published on 03/19/2026 at 13:30, 1 hour 31 minutes ago

ACCESS Newswire Reports Fourth Quarter and Full Year 2025 Results
Published on 03/19/2026 at 13:15, 1 hour 46 minutes ago

Worksport Presents New Premium "Game Changer" Tonneau Cover Model to Industry Buyers at Keystone BIG Show; Initiates Pre-Orders Ahead of Near-Term Commercial Launch

View all ACCESSWIRE

EQS Group

Published on 03/19/2026 at 14:51, 9 minutes ago

BeNEX opts for IVU.rail as its central IT system for operational planning
Published on 03/19/2026 at 14:30, 31 minutes ago

Surya Roshni Strengthens Germany Footprint with Successful Showcase at Light + Building 2026
Published on 03/19/2026 at 14:16, 44 minutes ago

From Kontron's point of view, current price distortions have no basis in Kontron's operating performance
Published on 03/19/2026 at 14:15, 46 minutes ago

Finexity AG: GBC Research initiates coverage with a target price of EUR 72.00
Published on 03/19/2026 at 13:43, 1 hour 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property plc

Les Echos

Published on 03/19/2026 at 15:00, 1 minute ago

Statement Accor
Published on 03/19/2026 at 15:00, 1 minute ago

Communication Accor
Published on 03/19/2026 at 08:45, 6 hours 16 minutes ago

Deezer et Sonos renouvellent et étendent leur partenariat stratégique
Published on 03/19/2026 at 08:45, 6 hours 16 minutes ago

Deezer and Sonos renew and expand long-term collaboration
Published on 03/19/2026 at 07:00, 8 hours 1 minute ago

bioMérieux Receives IVDR CE‑Marking for Two BIOFIRE® SPOTFIRE® Panels to Strengthen Near‑Patient Respiratory and Sore Throat Diagnostics Across Europe

View all LES ECHOS COMFI WIRE